Dogwood: Low Dose Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

 - IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo –

- Top-line results from the Bateman Horne Center’s Long-COVID study provide key insights into final design of Dogwood’s planned Phase 2 study, projected to enroll approximately 200 participants -

https://www.globenewswire.com/news-release/2024/11/18/2982814/0/en/Dogwood-Therapeutics-Inc-Announces-Low-Dose-IMC-2-Treatment-Reduces-Long-COVID-Related-Fatigue-and-Sleep-Disturbance-in-an-Investigator-Initiated-Study.html